We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Atherogenics (MM) | NASDAQ:AGIX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.07 | 0 | 01:00:00 |
Georgia
(State or other jurisdiction of incorporation) |
0-31261
(Commission File Number) |
58-2108232
(I.R.S. Employer Identification Number) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. | Other Events. |
Item 9.01. | Financial Statements and Exhibits. |
Exhibit No. | Description | |||||
99.1 | |
Press Release dated July 31, 2008
|
ATHEROGENICS, INC.
|
||||
Date: July 31, 2008 | /s/ MARK P. COLONNESE | |||
Mark P. Colonnese | ||||
Executive Vice President, Commercial Operations and Chief Financial Officer | ||||
Exhibit No. | Description | |||||
99.1 | |
Press Release dated July 31, 2008
|
1 Year Atherogenics Chart |
1 Month Atherogenics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions